In another study of anti‐PD‐1 in chronic HBV infection, there was a 0.57‐log reduction in HBsAg, including a sustained reduction in 2/15 participants,188 demonstrating that similar to outcomes from clinical trials in cancer, only a subset of participants appear to respond to anti‐PD‐1. This evidence concerns the gene PDCD1 and cancer.